NOVAVAX INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: Charles W. Newton

NOVAVAX INC.’s own tally for this item (“Elect Director: Charles W. Newton”): 42,892,746 for, 14,645,927 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the proposals considered and voted upon at the Annual Meeting, each of which were described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025, are as follows: Proposal 1 : Stockholders elected…”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 15,379,171 for, 1,109,703 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: John W. Shiver, Ph.D.

NOVAVAX INC.’s own tally for this item (“Elect Director: John W. Shiver”): 43,711,347 for, 13,838,060 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the proposals considered and voted upon at the Annual Meeting, each of which were described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025, are as follows: Proposal 1 : Stockholders elected…”
Support: 76% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 16,488,874 for.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: Rachel K. King

NOVAVAX INC.’s own tally for this item (“Elect Director: Rachel K. King”): 38,346,660 for, 19,134,990 against, per its Form 8-K filed June 24, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final voting results for the proposals considered and voted upon at the Annual Meeting, each of which were described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025, are as follows: Proposal 1 : Stockholders elected…”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 14,617,103 for, 1,856,222 against, 15,549 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The approval, on an advisory basis, of the compensation of our Named Executive Officers.

NOVAVAX INC.’s own tally for this item (“2. The compensation of the Company's named executive officers”): 41,390,651 for, 15,830,308 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 : Stockholders approved, on an advisory basis, the compensation of the Company's named executive officers:”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 52 managers: 15,830,539 for, 490,335 against, 168,000 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 218 managers: 14,079,594 for, 13,088,948 against, 36 abstained, 2 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

NOVAVAX INC.’s own tally for this item (“3. The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 79,306,893 for, 15,057,873 against — passed, per its Form 8-K filed June 24, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 : Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025:”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 16,486,634 for, 2,240 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.